NLRP3 and coronary artery disorder: Colchicine exerts anti-inflammatory effects by blocking the NLRP3 inflammasome, which is responsible for the production of IL-1β and IL-18.[162] These findings highlight the significance of inflammatory biomarkers in the development of CAD and propose their potential as promising tools in both diagnosis and prognosis.